Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe
Archives of Gynecology and Obstetrics · 18.04.2024 · 309 (6) · 2833-2841
DOI: 10.1007/s00404-024-07504-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Archives of Gynecology and Obstetrics, online erschienen am 18.04.2024. Verfasst von Sneha S Kelkar und 7 weiteren Autor:innen. Beteiligte Einrichtung: OPEN Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Microsatellite Instability, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck, Eisai Incorporated.
Abstract (Originalsprache)
Purpose
To assess the real-world prevalence of microsatellite instability (MSI)/mismatch repair (MMR) testing and related tumor status in recurrent/advanced endometrial cancer patients in Europe.
Methods
Data were from two multi-center, retrospective patient chart review studies conducted in the United Kingdom, Germany, Italy, France and Spain: The Endometrial Cancer Health Outcomes-Europe-First-Line (ECHO-EU-1L) study and the ECHO-EU-Second-Line (ECHO-EU-2L) study. ECHO-EU-1L included recurrent/advanced endometrial cancer patients who received first-line systemic therapy between 1/JUN/2016 and 31/MAR/2020 after recurrent/advanced diagnosis. ECHO-EU-2L included patients with recurrent/advanced endometrial cancer who progressed between 1/JUN/2016 and 30/JUN/2019 following prior first-line systemic therapy. Data collected included patient demographics, MSI/MMR tumor testing and results, and clinical/treatment characteristics.
Results
ECHO-EU-1L included 242 first-line patients and ECHO-EU-2L included 475 s-line patients. For all patients, median age at recurrent/advanced diagnosis was 69 years, roughly half had endometrioid carcinoma histology and over 75% had Stage IIIB-IV disease at initial diagnosis. The prevalence of MSI/MMR testing in the first-line and second-line cohorts was similar (36.4 and 34.9%, respectively). Among those tested, a majority had non-MSI-high/MMR proficient tumors (80.7 and 74.7% among first- and second-line patients, respectively). About 15% had MSI-high/MMR deficient tumors in both cohorts, and a few patients had discordant results (3.4 and 10.8% among first- and second-line patients, respectively).
Conclusion
Prior to the approvals of biomarker-directed therapies for recurrent/advanced endometrial cancer patients in Europe, there were low MSI/MMR testing rates for these patients of just over one-third. Given the availability of biomarker-directed therapies, increased MSI/MMR testing may help inform treatment decisions for recurrent/advanced endometrial cancer patients in Europe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- OPEN Health, Bethesda, MD, USA.
- Merck & Co., Inc., 126 East Lincoln Ave, P.O. Box 2000, Rahway, NJ, 07065, USA. vimalanand.prabhu@merck.com.
- Eisai Inc., Nutley, NJ, USA.
- M3 (EU) Ltd., Abingdon, UK.
- Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria.
Förderung
- Merck
- Eisai Incorporated
Zitieren
APA
Kelkar, S. S., Prabhu, V. S., Zhang, J., Ogando, Y. M., Roney, K., Verma, R. P., Miles, N., & Marth, C. (2024). Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe. Archives of Gynecology and Obstetrics, 309(6), 2833-2841. https://doi.org/10.1007/s00404-024-07504-3
Vancouver
Kelkar SS, Prabhu VS, Zhang J, Ogando YM, Roney K, Verma RP, et al. Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe. Archives of Gynecology and Obstetrics. 2024;309(6):2833-2841. doi:10.1007/s00404-024-07504-3
BibTeX
@article{Kelkar2024,
author = {Kelkar, Sneha S and Prabhu, Vimalanand S and Zhang, Jingchuan and Ogando, Yoscar M and Roney, Kyle and Verma, Rishi P and Miles, Nicola and Marth, Christian},
title = {Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe},
journal = {Archives of Gynecology and Obstetrics},
year = {2024},
volume = {309},
number = {6},
pages = {2833--2841},
doi = {10.1007/s00404-024-07504-3}
}
EUVIMED